Resistant hypertension is estimated to be present in 8-12% of all patients with hypertension. Indeed, despite multiple classes of medications and a recent consensus statement with a treatment algorithm, many patients still fail to reach blood pressure goals.
At #AHA22, a roundtable, case-based session focused on resistant hypertension and included discussions on the guidelines for treating hypertension, emerging therapeutic options, and real-world cases of patients with resistant hypertension. New therapies including baxdrostat, an inhibitor of aldosterone synthase, and renal denervation, offer great promise as therapeutic options for patients with resistant hypertension.